Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
MicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflectin...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full |
id |
doaj-0fce0d73d1a041b9ac949c865103fdbc |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Klara Cervena Klara Cervena Vendula Novosadova Barbara Pardini Barbara Pardini Alessio Naccarati Alessio Naccarati Alena Opattova Alena Opattova Alena Opattova Josef Horak Josef Horak Sona Vodenkova Sona Vodenkova Tomas Buchler Pavel Skrobanek Miroslav Levy Pavel Vodicka Pavel Vodicka Pavel Vodicka Veronika Vymetalkova Veronika Vymetalkova Veronika Vymetalkova |
spellingShingle |
Klara Cervena Klara Cervena Vendula Novosadova Barbara Pardini Barbara Pardini Alessio Naccarati Alessio Naccarati Alena Opattova Alena Opattova Alena Opattova Josef Horak Josef Horak Sona Vodenkova Sona Vodenkova Tomas Buchler Pavel Skrobanek Miroslav Levy Pavel Vodicka Pavel Vodicka Pavel Vodicka Veronika Vymetalkova Veronika Vymetalkova Veronika Vymetalkova Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients Frontiers in Oncology biomarker microRNA liquid biopsy plasma miR-122-5p miR-142-5p |
author_facet |
Klara Cervena Klara Cervena Vendula Novosadova Barbara Pardini Barbara Pardini Alessio Naccarati Alessio Naccarati Alena Opattova Alena Opattova Alena Opattova Josef Horak Josef Horak Sona Vodenkova Sona Vodenkova Tomas Buchler Pavel Skrobanek Miroslav Levy Pavel Vodicka Pavel Vodicka Pavel Vodicka Veronika Vymetalkova Veronika Vymetalkova Veronika Vymetalkova |
author_sort |
Klara Cervena |
title |
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients |
title_short |
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients |
title_full |
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients |
title_fullStr |
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients |
title_full_unstemmed |
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients |
title_sort |
analysis of microrna expression changes during the course of therapy in rectal cancer patients |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
MicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflecting disease course and treatment responses of RC patients. First, miRNA expression levels were assessed by next-generation sequencing in two plasma samplings (at the time of diagnosis and a year after) from 20 RC patients. MiR-122-5p and miR-142-5p were classified for subsequent validation in plasma and plasma extracellular vesicles (EVs) on an independent group of RC patients (n=107). Due to the intrinsic high differences in miRNA expression levels between samplings, cancer-free individuals (n=51) were included in the validation phase to determine the baseline expression levels of the selected miRNAs. Expression levels of these miRNAs were significantly different between RC patients and controls (for all p <0.001). A year after diagnosis, miRNA expression profiles were significantly modified in patients responding to treatment and were no longer different from those measured in cancer-free individuals. On the other hand, patients not responding to therapy maintained low expression levels in their second sampling (miR-122-5p: plasma: p=0.05, EVs: p=0.007; miR-142-5p: plasma: p=0.008). Besides, overexpression of miR-122-5p and miR-142-5p in RC cell lines inhibited cell growth and survival. This study provides novel evidence that circulating miR-122-5p and miR-142-5p have a high potential for RC screening and early detection as well as for the assessment of patients’ outcomes and the effectiveness of treatment schedule. |
topic |
biomarker microRNA liquid biopsy plasma miR-122-5p miR-142-5p |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full |
work_keys_str_mv |
AT klaracervena analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT klaracervena analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT vendulanovosadova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT barbarapardini analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT barbarapardini analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT alessionaccarati analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT alessionaccarati analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT josefhorak analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT josefhorak analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT sonavodenkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT sonavodenkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT tomasbuchler analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT pavelskrobanek analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT miroslavlevy analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients |
_version_ |
1717815430118113280 |
spelling |
doaj-0fce0d73d1a041b9ac949c865103fdbc2021-09-04T06:01:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.702258702258Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer PatientsKlara Cervena0Klara Cervena1Vendula Novosadova2Barbara Pardini3Barbara Pardini4Alessio Naccarati5Alessio Naccarati6Alena Opattova7Alena Opattova8Alena Opattova9Josef Horak10Josef Horak11Sona Vodenkova12Sona Vodenkova13Tomas Buchler14Pavel Skrobanek15Miroslav Levy16Pavel Vodicka17Pavel Vodicka18Pavel Vodicka19Veronika Vymetalkova20Veronika Vymetalkova21Veronika Vymetalkova22Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaCzech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Prague, CzechiaMolecular Genetics Epidemiology Unit, Italian Institute for Genomic Medicine, c/o IRCCS Candiolo,, Turin, ItalyCandiolo Cancer Institute, FPO-IRCCS, Candiolo, ItalyMolecular Genetics Epidemiology Unit, Italian Institute for Genomic Medicine, c/o IRCCS Candiolo,, Turin, ItalyCandiolo Cancer Institute, FPO-IRCCS, Candiolo, ItalyDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaThird Faculty of Medicine, Charles University, Prague, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaMicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflecting disease course and treatment responses of RC patients. First, miRNA expression levels were assessed by next-generation sequencing in two plasma samplings (at the time of diagnosis and a year after) from 20 RC patients. MiR-122-5p and miR-142-5p were classified for subsequent validation in plasma and plasma extracellular vesicles (EVs) on an independent group of RC patients (n=107). Due to the intrinsic high differences in miRNA expression levels between samplings, cancer-free individuals (n=51) were included in the validation phase to determine the baseline expression levels of the selected miRNAs. Expression levels of these miRNAs were significantly different between RC patients and controls (for all p <0.001). A year after diagnosis, miRNA expression profiles were significantly modified in patients responding to treatment and were no longer different from those measured in cancer-free individuals. On the other hand, patients not responding to therapy maintained low expression levels in their second sampling (miR-122-5p: plasma: p=0.05, EVs: p=0.007; miR-142-5p: plasma: p=0.008). Besides, overexpression of miR-122-5p and miR-142-5p in RC cell lines inhibited cell growth and survival. This study provides novel evidence that circulating miR-122-5p and miR-142-5p have a high potential for RC screening and early detection as well as for the assessment of patients’ outcomes and the effectiveness of treatment schedule.https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/fullbiomarkermicroRNAliquid biopsyplasmamiR-122-5pmiR-142-5p |